After identifying a common dependency of cisplatin‐resistant cancer cells upon extracellular glutamine, we then evaluate the utility of the long‐standing anti‐leukemic therapy asparaginase (ASNase)—which possesses both asparaginase and glutaminase activity—as a potential approach. The gene discussed is ASPG; the disease is cancer.